Science on CBD for Dogs: Latest Veterinary Studies

Evaluating the Evidence: What Science Says About CBD for Dogs

Two recently published veterinary studies provide new insights into the potential benefits and current limitations of cannabidiol (CBD) for dogs. Research teams in Chile and Thailand examined its role in canine oncology and epilepsy, moving the conversation beyond anecdotal claims into evidence-based science.

CBD Displays Anticancer Effects in Canine Cellular Models

Scientists from the Universidad de Chile conducted a systematic review of all existing studies on CBD for canine cancer. Fernando J. Medina and Claudio G. Torres compiled data from lab studies focused on six cancer types common in dogs: lymphoma, mammary cancer, glioma, prostate cancer, osteosarcoma, and urothelial carcinoma.

Their analysis, published in Frontiers in Veterinary Science, found consistent evidence that CBD exerts two primary anticancer effects. First, it acts as an antiproliferative agent, meaning it slows or stops the rapid division of cancer cells. Second, it is proapoptotic, triggering programmed cell death in malignant cells. The researchers identified specific intracellular signaling pathways involved, including ERK and JNK, which are crucial for cell survival and growth. By modulating these pathways, CBD disrupts the fundamental processes cancers need to spread.

Importantly, the review notes these findings are almost entirely from pre-clinical cellular models, not from clinical trials in dogs with cancer. Some studies evaluated combining CBD with common chemotherapy drugs, reporting mixed synergistic and antagonistic effects. This highlights a critical point: using CBD alongside conventional treatment should not be a pet owner’s decision, as it could unintentionally reduce the chemotherapy’s effectiveness.

Adjunctive CBD Reduces Seizure Frequency in Refractory Epilepsy

While the cancer research is confined to the lab, a clinical study from Kasetsart University in Thailand provides data from living patients. The team, led by K. Kimram, investigated CBD as an add-on treatment for dogs with refractory epilepsy—cases where standard medications like phenobarbital or potassium bromide fail to provide adequate control.

In this exploratory study, 14 dogs with refractory epilepsy were given a specific CBD oil formulation alongside their existing anti-seizure drugs for three months. The median monthly seizure frequency dropped from 4.5 episodes before the trial to 3.0 episodes during it, a 33% reduction. Five of the fourteen dogs (35.7%) achieved a 50% or greater reduction in their seizure frequency.

The study proposes a mechanism rooted in neurobiology. CBD influences the endocannabinoid system, a network of receptors throughout the central nervous system involved in regulating neuronal excitability. By enhancing the calming effect of the neurotransmitter GABA and potentially reducing inflammatory signals in the brain, CBD may raise the seizure threshold. The researchers also monitored blood levels of the common drug phenobarbital, noting that co-administration with CBD required careful dose monitoring to maintain therapeutic levels.

Navigating the Gap Between Promise and Clinical Practice

The combined findings illustrate both the potential and the current constraints of canine CBD use. For oncology, the promising lab results on cancer cell lines are a necessary first step, but they do not guarantee that orally administered CBD will effectively shrink tumors in a dog’s body. Factors like bioavailability—how much of the compound is absorbed and reaches the target tissue—are still being studied.

For epilepsy, the evidence is more direct, supporting a role for CBD as an adjunct therapy. However, the study’s sample size was small, and the optimal formulation and dose remain unclear. The CBD oil used in the Thai study contained specific supporting compounds, including omega-3 fatty acids and medium-chain triglycerides, which may influence its effects. This underlines a major challenge in the pet CBD market: products vary widely in concentration, purity, and additional ingredients, making consistent results difficult to achieve.

Veterinarians stress that CBD is not a substitute for proven therapies. For cancer, it should not delay surgery, radiation, or conventional chemotherapy. For conditions like epilepsy or chronic pain management, it may serve as a complementary tool within a broader plan that includes pharmaceuticals, physical therapy, or dietary management, as explored in our article on non-drug dog pain management.

A Practical Guide for Pet Owners Considering CBD

If you are considering CBD for your dog, a science-informed approach is essential. First, initiate the conversation with your veterinarian. Disclose all medications and supplements your dog takes, as CBD can interact with drugs processed by the liver, including many anti-seizure medications and pain relievers.

Seek products that provide a certificate of analysis (COA) from an independent third-party lab. This report verifies the CBD and THC concentrations and screens for contaminants like pesticides and heavy metals. Choose a formulation designed for pets, as some human products contain ingredients toxic to dogs, such as xylitol. Start with the lowest possible dose and monitor your dog closely for any changes in behavior, appetite, or gastrointestinal function.

Set realistic expectations. CBD is not a cure-all. In epilepsy, the goal is often a reduction in seizure frequency or severity, not a complete elimination. For cancer or arthritis, the aim may be supporting comfort and quality of life alongside standard care, similar to how dietary approaches are used in managing conditions like feline IBD.

Conclusion

Emerging research confirms biological mechanisms through which CBD may benefit dogs, particularly in managing refractory seizures and potentially impacting cancer growth at a cellular level. However, the transition from laboratory and initial clinical findings to standardized, reliable veterinary treatment protocols requires more extensive study. For now, CBD may represent a supplementary option under strict veterinary guidance.

Sources:
https://pubmed.ncbi.nlm.nih.gov/42254894/
https://pubmed.ncbi.nlm.nih.gov/41463899/
https://pubmed.ncbi.nlm.nih.gov/41389569/